Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Thursday, 5 January 2012
- Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept’s product candidate AZD1446 as a treatment for Alzheimer’s disease.
- Wednesday, 21 December 2011
- Dynavax and AstraZeneca agree to conduct toxicology studies for TLR-9 agonist for asthma Dynavax Technologies Corporation announced today they will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work performed by Dynavax under the recently amended collaboration agreement with AstraZeneca for the clinical development of AZD 1419. Development expenses will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6 million to begin the studies.
- Wednesday, 21 December 2011
- AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion